FLASH: New Low-Cost Options for Autoimmune Disorders

A few months ago, we added a new adalimumab product, Amjevita, to the Health Alliance^TM commercial formulary with prior authorization. In addition to Amjevita, Health Alliance will now be adding two new biosimilar adalimumab products, Hadlima and Adalimumab-adaz. All three biosimilars will be covered across all formularies, including Medicare, in parity with Humira. Health Alliance continues to be committed to offering members and providers access to biosimilars as they become available.